Group items tagged

A spinal cord injury typically occurs when significant damage is done to the spinal cord either from trauma, loss of normal blood supply, or ompression from infection or tumor. This infographic throwsmore light on the matter.

Palbace 125 Mg Capsules Suppliers-exporters India , Palbace a 125Mg Capsule is employed within the treatment of carcinoma. It's additionally wont to treat patients with bound varieties of carcinoma (estrogen receptor-positive, human stratum protein receptor 2-negative) that have unfold to alternative organs. it's given in conjunction with secretion malignant tumor therapies. We are leading suppliers & exporters of "Palbace 125Mg" in China, Russia, Hongkong, Bulgaria, Romania, India. We're largest suppliers of Pfizer India medicines & provide you the best price on Palbace 125Mg. The lowest price sellers, suppliers, distributors & Exporters from Delhi. For more info please contact us. Buy Online Palbace 125Mg Suppliers Price India Palbace 125Mg suppliers India Palbace 125mg Capsules Palbace (known as IBRANCE in other parts of the world) or palbociclib by Pfizer is a cancer drug that interferes with the growth and spread of cancer cells in the body. Description Brand Name: Palbace Generic Name: Palbociclib Strength: 125mg Packing: 21 Capsules in a bottle Form: Tablets Palbace125Mg is generally used in combination with letrozole or fulvestrant (Faslodex) for treating certain types of advanced breast cancer in postmenopausal women. It is also given in combination with another cancer medicine, either letrozole (Femara) or fulvestrant (Faslodex). Palbace is a renamed version of the drug Ibrance for the Indian market. It is verified by the US Food and Drug Administration (FDA). In clinical studies, palbociclib appeared to increase survival time of patients. Palbace comes in capsule form in 125 mg dose. 1 pack has 21 capsules. How Palbace125Mg capsules works ? Palbace 125mg capsule is an anti-cancer medication. It works by busy bodied with a enzyme, a sort of supermolecule within the body that helps management biological process. This stops cancer cells from dividing and growing. It is additionally won't to treat patients with bound kinds of carc

Presently, In the US, around 12% of women develop breast cancer over the course of their lifetime. In Canada, an estimated 26,900 women were expected to be diagnosed with breast cancer in 2019 and breast cancer accounts for nearly 25% of new cases of cancer among Canadian women. Download complete report summary @ http://bit.ly/2vsEa1D

After receiving approval from the National Institute for Health and Care Excellence (NICE), the NHS is preparing to roll out a new combination treatment for brain tumours in children and young people in England. Dabrafenib with trametinib would be the first ever targeted treatment for children (aged 1-17) with gliomas that have a specific genetic mutation, the health service said. The treatment, which can be taken at home, has been found to slow the progression of the disease by over threefold compared to standard chemotherapy in children with low-grade gliomas that have a BRAF V600E mutation. Clinical trials have shown that it causes fewer side-effects than chemotherapy. NICE approved the combination treatment on Wednesday 24 April. It will be available on the NHS in the coming months.

Germany-based OctreoPharm Sciences has received Orphan Drug Designation from the European Medicines Agency (EMA) for OPS202 as a diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors

Prostate specific antigen (PSA) is a serine prostate that is found only in the prostate within the epithelial cells of the acini and ducts. Normal PSA concentration in serum or plasma is 0.1-2.6ng/ml. Reports have suggested that elevated level of serum or plasma PSA is the most useful tumor markers in diagnosis of prostate cancer.

Patients with advanced non-small cell lung cancer (NSCLC) may soon be offered a blood test to assess their treatment options, instead of having to provide a tumour sample for analysis.

An oral drug combination by Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial. In the mid-stage trial, 47 per cent of the patients that were given the two drugs Tafinlar and Mekinist saw their tumours shrink, far above a rate of 11 per cent in a comparative group of participants on standard chemotherapy, the drugmaker said on Monday, June 6. The participants, aged one to 17 years, were suffering from low-grade gliomas (LGG), the most common childhood brain cancer. The trial only included those who were found to have a mutation known as BRAF V600, a genetic contributor in about 15 per cent to 20 per cent of paediatric LGG cases. Among further results of the trial with 110 participants, the median time without disease progression was 20.1 months for those given the Novartis drug combo, compared to 7.4 months on chemotherapy. The new oral treatment candidate also caused less severe side effects than burdensome chemotherapy.